@article {Tang2020.04.10.20060558, author = {Wei Tang and Zhujun Cao and Mingfeng Han and Zhengyan Wang and Junwen Chen and Wenjin Sun and Yaojie Wu and Wei Xiao and Shengyong Liu and Erzhen Chen and Wei Chen and Xiongbiao Wang and Jiuyong Yang and Jun Lin and Qingxia Zhao and Youqin Yan and Zhibin Xie and Dan Li and Yaofeng Yang and Leshan Liu and Jieming Qu and Guang Ning and Guochao Shi and Qing Xie}, title = {Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial}, elocation-id = {2020.04.10.20060558}, year = {2020}, doi = {10.1101/2020.04.10.20060558}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard-of-care (SOC) compared with SOC alone in adult patients with COVID-19.Design Multicenter, open-label, randomized controlled trial.Setting 16 government-designated COVID-19 treatment centers in China through 11 to 29 in February 2020.Participants 150 patients hospitalized with COVID-19. 75 patients were assigned to HCQ plus SOC and 75 were assigned to SOC alone (control group).Interventions HCQ was administrated with a loading dose of 1, 200 mg daily for three days followed by a maintained dose of 800 mg daily for the remaining days (total treatment duration: 2 or 3 weeks for mild/moderate or severe patients, respectively).Main outcome measures The primary endpoint was the 28-day negative conversion rate of SARS-CoV-2. The assessed secondary endpoints were negative conversion rate at day 4, 7, 10, 14 or 21, the improvement rate of clinical symptoms within 28-day, normalization of C-reactive protein and blood lymphocyte count within 28-day. Primary and secondary analysis was by intention to treat. Adverse events were assessed in the safety population.Results The overall 28-day negative conversion rate was not different between SOC plus HCQ and SOC group (Kaplan-Meier estimates 85.4\% versus 81.3\%, P=0.341). Negative conversion rate at day 4, 7, 10, 14 or 21 was also similar between the two groups. No different 28-day symptoms alleviation rate was observed between the two groups. A significant efficacy of HCQ on alleviating symptoms was observed when the confounding effects of anti-viral agents were removed in the post-hoc analysis (Hazard ratio, 8.83, 95\%CI, 1.09 to 71.3). This was further supported by a significantly greater reduction of CRP (6.986 in SOC plus HCQ versus 2.723 in SOC, milligram/liter, P=0.045) conferred by the addition of HCQ, which also led to more rapid recovery of lymphopenia, albeit no statistical significance. Adverse events were found in 8.8\% of SOC and 30\% of HCQ recipients with two serious adverse events. The most common adverse event in the HCQ recipients was diarrhea (10\%).Conclusions The administration of HCQ did not result in a higher negative conversion rate but more alleviation of clinical symptoms than SOC alone in patients hospitalized with COVID-19 without receiving antiviral treatment, possibly through anti-inflammatory effects. Adverse events were significantly increased in HCQ recipients but no apparently increase of serious adverse events.Trial registration ChiCTR2000029868.What is already known on this topic The potent in-vitro effects of hydroxychloroquine (HCQ) against SARS-CoV-2 has not convincingly been translated into clinical benefits in patients with COVID-19. A non-randomized trial showed significantly higher virus clearance rate at 6-day post inclusion in patients receiving 600mg hydroxychloroquine daily (N=20) than in patients with standard-of-care (N=16). In contrast, a randomized study of hydroxychloroquine published in Chinese showed no impact of hydroxychloroquine with a dose of 400mg hydroxychloroquine daily for 5 days on increasing virus negative conversion rate and alleviation of clinical symptoms in 30 patients with COVID-19.What this study adds In our multicenter, parallel, open-label randomized trial that included 150 adult patients hospitalized for COVID-19, adding hydroxychloroquine to the current standard-of-care in patients with COVID-19 does not increase virus response but accelerate the alleviation of clinical symptoms, possibly through anti-inflammatory properties and recovery of lymphopenia. Clinicians might consider hydroxychloroquine treatment in symptomatic patients with elevated CRP and/or lymphopenia because hydroxychloroquine might prevent disease progression, particularly in patients at higher risk.Side effects of HCQ should be closely monitored, although no apparent safety concerns were observed in our trial using HCQ with a loading dose of 1, 200 mg daily for three days followed by a maintained dose of 800 mg daily for the remaining days (total treatment duration: 2 or 3 weeks for mild/moderate or severe patients, respectively).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000029868Funding StatementThis work was supported by the Emergent Projects of National Science and Technology (2020YFC0844500), National Natural Science Foundation of China (81970020, 81770025), National Key Research and Development Program of China (2016YFC0901104), Shanghai Municipal Key Clinical Specialty (shslczdzk02202, shslczdzk01103), National Innovative Research Team of High-level Local Universities in Shanghai, Shanghai Key Discipline for Respiratory Diseases (2017ZZ02014), National Major Scientific and Technological Special Project for Significant New Drugs Development (2017ZX09304007), Key Projects in the National Science and Technology Pillar Program during the Thirteenth Five-year Plan Period (2018ZX09206005-004, 2017ZX10202202-005-004, 2017ZX10203201-008). The funders played no role in study design, data collection, data analysis, data interpretation, or reporting. The guarantors had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, and had final responsibility for the decision to submit for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized datasets can be made available on reasonable request after approval from the trial management committee and after signing a data access agreement. Proposals should be directed to the corresponding author.}, URL = {https://www.medrxiv.org/content/early/2020/04/14/2020.04.10.20060558}, eprint = {https://www.medrxiv.org/content/early/2020/04/14/2020.04.10.20060558.full.pdf}, journal = {medRxiv} }